Tinnemans J G, Wobbes T, van der Sluis R F, Lubbers E J, de Boer H H
Am J Surg. 1986 Mar;151(3):334-8. doi: 10.1016/0002-9610(86)90462-9.
During a 9 year period, 300 consecutive women underwent breast biopsies solely because of nonpalpable, mammographically suspicous findings. One hundred clinically occult breast carcinomas were found, 65 of which were invasive and 35 noninvasive. Eighty-three mastectomy specimens were evaluable for evidence of multifocal carcinoma in another quadrant of the breast or at a distance of 5 cm and residual cancer outside the excisional biopsy cavity. Multicentricity was present in 47 percent and residual tumor in 60 percent of the whole group. When only clinically occult invasive carcinomas were considered, other foci of invasive carcinoma were demonstrated in 26 percent of the patients and residual invasive cancer in 35 percent. The rate of bilaterality was 14 percent, occurring synchronously in 11 percent of the patients. Any therapeutic procedure for nonpalpable breast carcinoma, whether invasive or noninvasive ductal carcinoma, should be directed to the whole breast. Mammography of the contralateral side should be an integral part of the preoperative work-up of patients with palpable lesions ipsilaterally.
在9年期间，300名连续的女性仅因乳腺钼靶检查发现可疑但触诊未及的病变而接受了乳房活检。发现了100例临床隐匿性乳腺癌，其中65例为浸润性，35例为非浸润性。83例乳房切除术标本可用于评估乳腺另一象限或距切除活检腔5厘米处是否存在多灶性癌以及切除活检腔外是否有残留癌。整个组中多中心性的发生率为47%，残留肿瘤的发生率为60%。仅考虑临床隐匿性浸润性癌时，26%的患者发现了其他浸润性癌灶，35%的患者发现了残留浸润性癌。双侧性发生率为14%，11%的患者为同时性双侧发病。对于临床隐匿性乳腺癌，无论为浸润性还是非浸润性导管癌。任何治疗方法都应针对整个乳房。对患侧有可触及病变的患者进行术前检查时，对侧乳房的钼靶检查应作为不可或缺的一部分。
